TFA
NBIX icon

Transamerica Financial Advisors’s Neurocrine Biosciences NBIX Stock Holding History

Transamerica Financial Advisors’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.7K Buy
283
+144
+104% +$21.4K ﹤0.01% 706
2026
Q1 		$18.3K Buy
139
+57
+70% +$7.56K ﹤0.01% 823
2025
Q4 		$11.6K Buy
82
+43
+110% +$6.23K ﹤0.01% 824
2025
Q3 		$5.47K Buy
+39
New +$5.28K ﹤0.01% 846

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Transamerica Financial Advisors's NBIX Position: Q2 2026 in Review

Transamerica Financial Advisors increased its Neurocrine Biosciences (NBIX) stake by 104% in Q2 2026, buying an estimated $21.4K and bringing the position to 283 shares worth $47.7K. The position accounts for ﹤0.01% of the portfolio, ranked #706.

Transamerica Financial Advisors first reported a position in NBIX in Q3 2025 and has held it in 4 quarters since. 775 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Transamerica Financial Advisors held 283 shares of Neurocrine Biosciences worth $47.7K as of Q2 2026.
  • Transamerica Financial Advisors bought 144 Neurocrine Biosciences shares in Q2 2026, an estimated $21.4K.
  • Neurocrine Biosciences made up ﹤0.01% of Transamerica Financial Advisors's portfolio in Q2 2026, its #706 holding.
  • Transamerica Financial Advisors first reported a position in Neurocrine Biosciences in Q3 2025 and has held it in 4 quarters since.
  • 775 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Transamerica Financial Advisors's 13F filing for Q2 2026, filed 17 Aug 2026.